The abstract is read at the publisher; the summary is JClub's.
AI-assisted SNF subtyping in stage II–III HR+/HER2− breast cancer is linked to higher neoadjuvant pCR with precision treatment, especially in the targeted-based group (13.9% vs 4.0%).
- Why it matters: Neoadjuvant therapy for HR+/HER2− breast cancer needs better patient selection to improve pathological complete response while keeping toxicity manageable.
- What they did: In this phase 2 randomized trial (NCT05582499), 251 patients were assigned 1:1 to precision versus control after digital pathology SNF subtyping into endocrine-based (49) and targeted-based (202) groups.
- The result: Precision treatment increased pCR overall (11.1% vs 4.0%; p = 0.033), with the main benefit in the targeted-based group (13.9% vs 4.0%; p = 0.026), and toxicity remained manageable.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.